Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9205630 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL5465849 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL5467589 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL465480 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL465471 | 1.00 | — | — | |
| SCHEMBL5471582 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL7697182 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL277225 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL95733 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL4399689 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| EP-1715862-A1 | KINASE INHIBITORS | Devgen NV (BE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005082367-A1 | KINASE INHIBITORS | DEVGEN NV (BE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | TSHR 3553/4885THRB 2167/4885MEN1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.